Patent Issued for Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative (USPTO 11944597).

A patent has been issued for the pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative. The patent describes pharmaceutical compositions that include an immediate release component and a modified release component, which can be used to treat various conditions such as narcolepsy, excessive daytime sleepiness, cataplexy, Parkinson's disease, multiple sclerosis, fibromyalgia, and more. The patent also provides methods for administering the pharmaceutical composition to patients in need of treatment. The patent is assigned to Xwpharma Ltd. and was filed on October 26, 2022. [Extracted from the article]

Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)